Mineralys Therapeutics (MLYS)
Mineralys Therapeutics on one page: short interest, daily short volume, fails to deliver, planned sales, large holders, 13F holders, earnings dates and insider trades. Listed on Nasdaq, classified by the SEC as pharmaceutical preparations.
7.4M
Short interest
settlement 2026-10-15
5.3
Days to cover
+0.2 days vs prior
19.9%
Short share of volume
2026-11-02
1,330
Fails to deliver
settlement 2026-10-02
Mon 9 Nov
Next earnings
estimated date
-$5.5M
Insider flow, 90 days
0 buys, 6 sells
As of 2026-11-02.
Short interest
FINRA, twice a month. The newest 48 settlements in the table, 48 in the chart. JSONAs of 15 October 2026, short interest in MLYS is 7,438,452 shares, down 1,743,439 shares over the last month. Over the last 48 readings it ranged from 1,300,184 shares (15 November 2024) to 11,098,105 shares (30 June 2026). At the reported average volume of 1.4M shares a day that is 5.3 days to cover.
Embed this chart.The embed keeps its attribution line.
<iframe src="https://xoomar.com/embed/stocks/mlys" width="100%" height="440" style="border:0;max-width:100%" loading="lazy" title="XOOMAR chart"></iframe>
| Settlement | Shares short | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|
| 2026-10-15 | 7,438,452 | -4.7% | 1,396,159 | 5.33 |
| 2026-09-30 | 7,805,612 | -15.0% | 1,513,825 | 5.16 |
| 2026-09-15 | 9,181,891 | -1.6% | 1,443,814 | 6.36 |
| 2026-08-31 | 9,332,307 | -3.3% | 818,574 | 11.40 |
| 2026-08-14 | 9,645,951 | +3.6% | 744,755 | 12.95 |
| 2026-07-31 | 9,313,645 | -2.5% | 618,178 | 15.07 |
| 2026-07-15 | 9,552,513 | -13.9% | 976,498 | 9.78 |
| 2026-06-30 | 11,098,105 | +27.6% | 2,116,023 | 5.24 |
| 2026-06-15 | 8,698,119 | -8.2% | 2,484,224 | 3.50 |
| 2026-05-29 | 9,477,459 | +5.0% | 1,389,885 | 6.82 |
| 2026-05-15 | 9,024,879 | +5.8% | 1,102,043 | 8.19 |
| 2026-04-30 | 8,531,291 | -2.8% | 870,080 | 9.81 |
| 2026-04-15 | 8,778,401 | +4.9% | 1,348,376 | 6.51 |
| 2026-03-31 | 8,370,090 | -6.5% | 1,460,576 | 5.73 |
| 2026-03-13 | 8,948,568 | -6.9% | 1,338,181 | 6.69 |
| 2026-02-27 | 9,607,513 | -3.8% | 866,741 | 11.08 |
| 2026-02-13 | 9,982,346 | -1.2% | 1,289,198 | 7.74 |
| 2026-01-30 | 10,102,051 | -2.0% | 947,605 | 10.66 |
| 2026-01-15 | 10,304,718 | +11.5% | 1,378,178 | 7.48 |
| 2025-12-31 | 9,242,605 | +16.3% | 1,563,676 | 5.91 |
| 2025-12-15 | 7,948,340 | +7.3% | 1,425,894 | 5.57 |
| 2025-11-28 | 7,405,674 | +7.5% | 1,451,362 | 5.10 |
| 2025-11-14 | 6,889,251 | +0.7% | 2,245,872 | 3.07 |
| 2025-10-31 | 6,844,921 | -4.0% | 853,554 | 8.02 |
| 2025-10-15 | 7,132,486 | +3.6% | 1,269,428 | 5.62 |
| 2025-09-30 | 6,883,171 | -9.2% | 1,631,374 | 4.22 |
| 2025-09-15 | 7,579,857 | -0.5% | 4,284,625 | 1.77 |
| 2025-08-29 | 7,617,115 | +2.8% | 991,460 | 7.68 |
| 2025-08-15 | 7,408,973 | +5.9% | 865,276 | 8.56 |
| 2025-07-31 | 6,996,921 | -11.1% | 737,004 | 9.49 |
| 2025-07-15 | 7,867,965 | +2.6% | 558,692 | 14.08 |
| 2025-06-30 | 7,667,206 | +24.3% | 1,220,051 | 6.28 |
| 2025-06-13 | 6,168,786 | +0.1% | 509,706 | 12.10 |
| 2025-05-30 | 6,163,892 | -14.5% | 813,351 | 7.58 |
| 2025-05-15 | 7,206,718 | +12.1% | 915,852 | 7.87 |
| 2025-04-30 | 6,430,393 | +5.5% | 572,112 | 11.24 |
| 2025-04-15 | 6,091,993 | +29.4% | 1,330,104 | 4.58 |
| 2025-03-31 | 4,708,751 | +112.3% | 1,345,091 | 3.50 |
| 2025-03-14 | 2,217,881 | +10.1% | 2,743,062 | 1.00 |
| 2025-02-28 | 2,013,841 | +15.4% | 435,316 | 4.63 |
| 2025-02-14 | 1,745,648 | -6.3% | 286,559 | 6.09 |
| 2025-01-31 | 1,862,767 | -0.5% | 229,141 | 8.13 |
| 2025-01-15 | 1,871,588 | +2.4% | 295,172 | 6.34 |
| 2024-12-31 | 1,827,351 | +15.2% | 207,620 | 8.80 |
| 2024-12-13 | 1,586,204 | +12.2% | 163,370 | 9.71 |
| 2024-11-29 | 1,413,299 | +8.7% | 159,450 | 8.86 |
| 2024-11-15 | 1,300,184 | -6.5% | 312,973 | 4.15 |
| 2024-10-31 | 1,389,795 | -13.8% | 115,603 | 12.02 |
Daily short volume
FINRA Reg SHO, the last 30 sessions. JSONAs of 2 November 2026, the short share of MLYS volume is 19.9%, down 3.5 points over the last five sessions. Over the last 30 readings it ranged from 15.0% (27 October 2026) to 67.6% (15 October 2026). The latest reading sits at the bottom of that range. The latest reading is 21.2 points below the 30-session average of 41.2%, on 1.7M shares reported.
| Date | Short volume | Total volume | Short share | Exempt |
|---|---|---|---|---|
| 2026-11-02 | 330K | 1.7M | 19.9% | 16,992 |
| 2026-10-30 | 229K | 1.5M | 15.0% | 1,889 |
| 2026-10-29 | 177K | 959K | 18.5% | 0 |
| 2026-10-28 | 152K | 498K | 30.6% | 0 |
| 2026-10-27 | 164K | 1.1M | 15.0% | 0 |
| 2026-10-26 | 78K | 334K | 23.4% | 5 |
| 2026-10-23 | 202K | 436K | 46.3% | 0 |
| 2026-10-22 | 170K | 307K | 55.3% | 5,225 |
| 2026-10-21 | 155K | 283K | 54.8% | 0 |
| 2026-10-20 | 172K | 385K | 44.6% | 0 |
| 2026-10-19 | 258K | 571K | 45.2% | 0 |
| 2026-10-16 | 246K | 418K | 58.9% | 334 |
| 2026-10-15 | 293K | 434K | 67.6% | 0 |
| 2026-10-14 | 175K | 426K | 41.0% | 0 |
| 2026-10-13 | 348K | 1.0M | 34.5% | 0 |
| 2026-10-12 | 153K | 321K | 47.6% | 0 |
| 2026-10-09 | 142K | 346K | 41.1% | 0 |
| 2026-10-08 | 306K | 726K | 42.2% | 0 |
| 2026-10-07 | 190K | 401K | 47.4% | 0 |
| 2026-10-06 | 159K | 593K | 26.9% | 0 |
| 2026-10-05 | 245K | 530K | 46.3% | 0 |
| 2026-10-02 | 167K | 321K | 51.9% | 0 |
| 2026-10-01 | 365K | 724K | 50.4% | 0 |
| 2026-09-30 | 433K | 803K | 54.0% | 32,510 |
| 2026-09-29 | 304K | 492K | 61.8% | 0 |
| 2026-09-28 | 121K | 547K | 22.1% | 0 |
| 2026-09-25 | 156K | 484K | 32.3% | 0 |
| 2026-09-24 | 207K | 340K | 61.0% | 4,723 |
| 2026-09-23 | 224K | 654K | 34.2% | 0 |
| 2026-09-22 | 106K | 234K | 45.1% | 0 |
Fails to deliver
SEC, the last 30 settlement dates with a fail. JSONAs of 2 October 2026, the fails-to-deliver balance in MLYS is 1,330 shares, down 8,890 shares over the last settlement date. Over the last 30 readings it ranged from 2 shares (17 July 2026) to 28,905 shares (3 September 2026). The latest reading sits at the bottom of that range.
| Settlement | Shares failed | Price | Value |
|---|---|---|---|
| 2026-10-02 | 1,330 | $23.72 | $32K |
| 2026-10-01 | 10,220 | $25.13 | $257K |
| 2026-09-08 | 781 | $28.21 | $22K |
| 2026-09-03 | 28,905 | $29.04 | $839K |
| 2026-08-21 | 12,979 | $25.75 | $334K |
| 2026-08-20 | 16,333 | $26.95 | $440K |
| 2026-08-19 | 3,766 | $26.61 | $100K |
| 2026-08-06 | 5,550 | $26.85 | $149K |
| 2026-08-05 | 32 | $26.50 | $848 |
| 2026-08-04 | 5,543 | $25.78 | $143K |
| 2026-08-03 | 360 | $25.52 | $9K |
| 2026-07-27 | 575 | $26.71 | $15K |
| 2026-07-22 | 81 | $27.52 | $2K |
| 2026-07-20 | 297 | $27.09 | $8K |
| 2026-07-17 | 2 | $27.08 | $54 |
| 2026-07-06 | 722 | $27.69 | $20K |
| 2026-07-02 | 780 | $26.89 | $21K |
| 2026-07-01 | 57 | $26.98 | $2K |
| 2026-06-30 | 1,988 | $26.88 | $53K |
| 2026-06-15 | 2,404 | $23.62 | $57K |
| 2026-06-11 | 9,092 | $23.76 | $216K |
| 2026-05-22 | 3 | $30.23 | $91 |
| 2026-04-24 | 6,064 | $28.49 | $173K |
| 2026-04-22 | 41 | $28.78 | $1K |
| 2026-04-20 | 8,263 | $30.58 | $253K |
| 2026-04-09 | 170 | $27.76 | $5K |
| 2026-04-02 | 151 | $26.41 | $4K |
| 2026-03-19 | 190 | $23.90 | $5K |
| 2026-01-23 | 5,424 | $34.28 | $186K |
| 2026-01-20 | 100 | $32.74 | $3K |
Insider trades
SEC Form 4, newest first. JSONInsiders at MLYS reported 6 open-market sells worth $5.5M in the last 90 days and no open-market buys. Latest filing: COATS LONNEL (Director) on 2026-10-19.
| Date | Insider | Title | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|---|
| 2026-10-19 | COATS LONNEL | Director | Grant | 12K | $0.00 | $0 | 12K |
| 2026-10-19 | Peterson Kristine | Director | Grant | 12K | $0.00 | $0 | 12K |
| 2026-09-30 | Congleton Jon | Chief Executive Officer | Sell | 75K | $25.46 | $1.9M | 529K |
| 2026-09-22 | Slingsby Brian Taylor | Director | Sell | 104K | $28.81 | $3.0M | 7.8M |
| 2026-09-21 | Warren Eric | Chief Commercial Officer | Sell | 7K | $28.12 | $209K | 38K |
| 2026-09-21 | Warren Eric | Chief Commercial Officer | Exercise or conversion | 7K | $13.24 | $98K | 46K |
| 2026-09-15 | Karydas Daphne | Director | Sell | 3K | $28.58 | $86K | 6K |
| 2026-09-15 | Karydas Daphne | Director | Exercise or conversion | 3K | $12.02 | $36K | 9K |
| 2026-08-21 | Warren Eric | Chief Commercial Officer | Sell | 7K | $25.98 | $193K | 38K |
| 2026-08-21 | Warren Eric | Chief Commercial Officer | Exercise or conversion | 7K | $13.24 | $98K | 46K |
| 2026-08-10 | Rodman David Malcom | Chief Medical Officer | Sell | 2K | $27.09 | $59K | 51K |
| 2026-08-10 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 2K | $16.00 | $35K | 54K |
| 2026-08-10 | Ferguson James J. III | Chief Medical Officer | Grant | 102K | $0.00 | $0 | 102K |
| 2026-07-21 | Warren Eric | Chief Commercial Officer | Sell | 7K | $26.87 | $200K | 38K |
| 2026-07-21 | Warren Eric | Chief Commercial Officer | Exercise or conversion | 7K | $13.24 | $98K | 46K |
| 2026-07-17 | Rodman David Malcom | Chief Medical Officer | Sell | 416 | $26.53 | $11K | 51K |
| 2026-07-17 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 416 | $15.44 | $6K | 52K |
| 2026-07-15 | Rodman David Malcom | Chief Medical Officer | Sell | 6K | $26.61 | $169K | 51K |
| 2026-07-13 | Rodman David Malcom | Chief Medical Officer | Sell | 14K | $27.58 | $388K | 58K |
| 2026-07-13 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 6K | $1.08 | $7K | 72K |
| 2026-07-13 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 4K | $14.25 | $59K | 65K |
| 2026-07-13 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 4K | $10.20 | $36K | 61K |
| 2026-07-13 | Congleton Jon | Chief Executive Officer | Sell | 11K | $27.24 | $291K | 604K |
| 2026-07-09 | Rodman David Malcom | Chief Medical Officer | Sell | 2K | $30.30 | $66K | 58K |
| 2026-07-09 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 2K | $16.00 | $35K | 60K |
| 2026-06-30 | Congleton Jon | Chief Executive Officer | Sell | 58K | $25.94 | $1.5M | 631K |
| 2026-06-30 | Congleton Jon | Chief Executive Officer | Sell | 17K | $26.82 | $456K | 614K |
| 2026-06-26 | Warren Eric | Chief Commercial Officer | Sell | 104K | $25.90 | $2.7M | 38K |
| 2026-06-26 | Warren Eric | Chief Commercial Officer | Exercise or conversion | 104K | $13.24 | $1.4M | 143K |
| 2026-06-17 | Karydas Daphne | Director | Sell | 3K | $25.00 | $75K | 6K |
| 2026-06-17 | Karydas Daphne | Director | Exercise or conversion | 3K | $12.02 | $36K | 9K |
| 2026-06-17 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 4K | $14.25 | $59K | 61K |
| 2026-06-17 | Rodman David Malcom | Chief Medical Officer | Sell | 5K | $25.00 | $115K | 57K |
| 2026-06-17 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 417 | $15.44 | $6K | 62K |
| 2026-06-15 | Rodman David Malcom | Chief Medical Officer | Sell | 10K | $23.81 | $235K | 57K |
| 2026-06-15 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 4K | $10.20 | $36K | 67K |
| 2026-06-12 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 6K | $1.08 | $7K | 70K |
| 2026-06-12 | Rodman David Malcom | Chief Medical Officer | Sell | 6K | $23.93 | $152K | 63K |
| 2026-06-10 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 2K | $16.00 | $35K | 66K |
| 2026-06-10 | Rodman David Malcom | Chief Medical Officer | Sell | 2K | $25.00 | $54K | 63K |
| 2026-05-18 | Rodman David Malcom | Chief Medical Officer | Sell | 417 | $27.55 | $11K | 63K |
| 2026-05-18 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 417 | $15.44 | $6K | 64K |
| 2026-05-13 | Rodman David Malcom | Chief Medical Officer | Sell | 14K | $28.58 | $402K | 63K |
| 2026-05-13 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 4K | $14.25 | $59K | 77K |
| 2026-05-13 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 4K | $10.20 | $36K | 73K |
| 2026-05-12 | Rodman David Malcom | Chief Medical Officer | Sell | 6K | $29.36 | $186K | 70K |
| 2026-05-12 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 6K | $1.08 | $7K | 76K |
| 2026-05-11 | Rodman David Malcom | Chief Medical Officer | Sell | 2K | $29.71 | $65K | 70K |
| 2026-05-11 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 2K | $16.00 | $35K | 72K |
| 2026-04-17 | Rodman David Malcom | Chief Medical Officer | Sell | 416 | $31.33 | $13K | 70K |
| 2026-04-17 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 416 | $15.44 | $6K | 70K |
| 2026-04-15 | Rodman David Malcom | Chief Medical Officer | Sell | 6K | $27.66 | $176K | 70K |
| 2026-04-13 | Rodman David Malcom | Chief Medical Officer | Sell | 14K | $26.54 | $373K | 76K |
| 2026-04-13 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 4K | $14.25 | $59K | 90K |
| 2026-04-13 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 4K | $10.20 | $36K | 86K |
| 2026-04-13 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 6K | $1.08 | $7K | 82K |
| 2026-04-13 | Congleton Jon | Chief Executive Officer | Sell | 16K | $26.83 | $422K | 689K |
| 2026-04-09 | Rodman David Malcom | Chief Medical Officer | Sell | 2K | $27.38 | $59K | 76K |
| 2026-04-09 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 2K | $16.00 | $35K | 78K |
| 2026-03-31 | Karydas Daphne | Director | Sell | 3K | $25.00 | $75K | 6K |
| 2026-03-31 | Karydas Daphne | Director | Exercise or conversion | 3K | $12.02 | $36K | 9K |
| 2026-03-31 | Congleton Jon | Chief Executive Officer | Sell | 453 | $27.05 | $12K | 705K |
| 2026-03-31 | Congleton Jon | Chief Executive Officer | Sell | 55K | $26.54 | $1.5M | 706K |
| 2026-03-31 | Congleton Jon | Chief Executive Officer | Sell | 19K | $25.50 | $494K | 761K |
| 2026-03-30 | Shah Rajeev M. | Director | Buy | 58K | $24.16 | $1.4M | 5.8M |
| 2026-03-30 | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | 58K | $24.16 | $1.4M | 5.8M |
| 2026-03-27 | Shah Rajeev M. | Director | Buy | 311K | $23.67 | $7.4M | 5.8M |
| 2026-03-27 | RA CAPITAL MANAGEMENT, L.P. | Director | Buy | 311K | $23.67 | $7.4M | 5.8M |
| 2026-03-17 | Rodman David Malcom | Chief Medical Officer | Sell | 417 | $25.65 | $11K | 76K |
| 2026-03-17 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 417 | $15.44 | $6K | 77K |
| 2026-03-13 | Rodman David Malcom | Chief Medical Officer | Sell | 253 | $27.82 | $7K | 76K |
| 2026-03-13 | Rodman David Malcom | Chief Medical Officer | Sell | 3K | $27.37 | $84K | 76K |
| 2026-03-13 | Rodman David Malcom | Chief Medical Officer | Sell | 11K | $25.91 | $278K | 79K |
| 2026-03-13 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 4K | $14.25 | $59K | 90K |
| 2026-03-13 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 4K | $10.20 | $36K | 86K |
| 2026-03-12 | Rodman David Malcom | Chief Medical Officer | Sell | 6K | $27.37 | $174K | 82K |
| 2026-03-12 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 6K | $1.08 | $7K | 89K |
| 2026-03-09 | Rodman David Malcom | Chief Medical Officer | Sell | 2K | $26.84 | $58K | 82K |
| 2026-03-09 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 2K | $16.00 | $35K | 85K |
| 2026-02-19 | Slingsby Brian Taylor | Director, 10% owner | Other transaction | 6K | $0.00 | $0 | 7.9M |
| 2026-02-19 | RA Capital Healthcare Fund LP | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2026-02-19 | SBLENDORIO GLENN | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2026-02-19 | Slingsby Brian Taylor | Director, 10% owner | Other transaction | 6K | $0.00 | $0 | 0 |
| 2026-02-19 | Slingsby Brian Taylor | Director, 10% owner | Grant | 6K | $0.00 | $0 | 6K |
| 2026-02-19 | Rodman David Malcom | Chief Medical Officer | Grant | 38K | $0.00 | $0 | 82K |
| 2026-02-19 | Levy Adam Scott | CFO and Secretary | Grant | 40K | $0.00 | $0 | 49K |
| 2026-02-19 | RA CAPITAL MANAGEMENT, L.P. | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2026-02-19 | Karydas Daphne | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2026-02-19 | Gold Alexander M | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2026-02-19 | DiRocco Derek | Director | Grant | 6K | $0.00 | $0 | 6K |
| 2026-02-19 | Congleton Jon | Chief Executive Officer | Grant | 141K | $0.00 | $0 | 780K |
| 2026-02-19 | AKKARAJU SRINIVAS | Director, 10% owner | Grant | 6K | $0.00 | $0 | 6K |
| 2026-02-17 | Rodman David Malcom | Chief Medical Officer | Sell | 417 | $27.59 | $12K | 44K |
| 2026-02-17 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 417 | $15.44 | $6K | 45K |
| 2026-02-13 | Rodman David Malcom | Chief Medical Officer | Sell | 6K | $27.58 | $175K | 44K |
| 2026-02-13 | Rodman David Malcom | Chief Medical Officer | Sell | 4K | $27.33 | $114K | 50K |
| 2026-02-13 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 4K | $14.25 | $59K | 55K |
| 2026-02-13 | Rodman David Malcom | Chief Medical Officer | Sell | 4K | $27.33 | $97K | 50K |
| 2026-02-13 | Rodman David Malcom | Chief Medical Officer | Exercise or conversion | 4K | $10.20 | $36K | 54K |
| 2026-02-12 | Rodman David Malcom | Chief Medical Officer | Sell | 521 | $29.64 | $15K | 50K |
Form 4 filings are due within two business days of the trade. Insiders sell for many reasons that say nothing about the company; open-market buys are rarer.
Planned sales (Form 144)
Newest first. JSON50 Form 144 notices on file for MLYS worth $19.2M at the prices reported; 12 in the last 90 days worth $6.2M. Latest: Rodman David Malcom filed on 2026-10-13 to sell 3,542 shares ($78K) from 2026-10-13.
| Filed | Seller | Shares | Market value | Of outstanding | Sale from | Broker |
|---|---|---|---|---|---|---|
| 2026-10-13 | Rodman David MalcomOfficer | 4K | $78K | 0.004% | 2026-10-13 | Merrill Lynch |
| 2026-09-30 | Congleton JonOfficer, Director | 75K | $1.9M | 0.085% | 2026-09-30 | Merrill Lynch |
| 2026-09-22 | CATALYS PACIFIC FUND LPDirector | 104K | $3.0M | 0.118% | 2026-09-22 | Morgan Stanley Smith Barney LLC Executive Financial Services |
| 2026-09-21 | Warren EricOfficer | 7K | $209K | 0.008% | 2026-09-21 | Merrill Lynch |
| 2026-09-17 | Rodman David MalcomOfficer | 417 | $12K | 0.000% | 2026-09-17 | Merrill Lynch |
| 2026-09-15 | Karydas DaphneOfficer | 3K | $86K | 0.003% | 2026-09-15 | Merrill Lynch |
| 2026-09-14 | Rodman David MalcomOfficer | 8K | $217K | 0.009% | 2026-09-14 | Merrill Lynch |
| 2026-09-09 | Rodman David MalcomOfficer | 2K | $67K | 0.002% | 2026-09-09 | Merrill Lynch |
| 2026-08-21 | Warren EricOfficer | 7K | $193K | 0.008% | 2026-08-21 | Merrill Lynch |
| 2026-08-17 | Rodman David MalcomOfficer | 417 | $11K | 0.001% | 2026-08-17 | Merrill Lynch |
| 2026-08-13 | Rodman David MalcomOfficer | 14K | $372K | 0.017% | 2026-08-13 | Merrill Lynch |
| 2026-08-10 | Rodman David MalcomOfficer | 2K | $59K | 0.003% | 2026-08-10 | Merrill Lynch |
| 2026-07-21 | Warren EricOfficer | 7K | $200K | 0.009% | 2026-07-21 | Merrill Lynch |
| 2026-07-17 | Rodman David MalcomOfficer | 416 | $11K | 0.001% | 2026-07-17 | Merrill Lynch |
| 2026-07-15 | Rodman David MalcomOfficer | 6K | $169K | 0.008% | 2026-07-15 | Merrill Lynch |
| 2026-07-14 | Rodman David MalcomOfficer | 14K | $388K | 0.017% | 2026-07-13 | Merrill Lynch |
| 2026-07-13 | Rodman David MalcomOfficer | 15K | $388K | 0.018% | 2026-07-13 | Merrill Lynch |
| 2026-07-13 | Congleton JonOfficer, Director | 11K | $291K | 0.013% | 2026-07-13 | Merrill Lynch |
| 2026-07-09 | Rodman David MalcomOfficer | 2K | $66K | 0.003% | 2026-07-09 | Merrill Lynch |
| 2026-06-30 | Congleton JonOfficer | 75K | $2.0M | 0.091% | 2026-06-30 | Merrill Lynch |
| 2026-06-29 | Warren EricOfficer | 104K | $2.7M | 0.126% | 2026-06-26 | Merrill Lynch |
| 2026-06-17 | Rodman David MalcomOfficer | 5K | $115K | 0.006% | 2026-06-17 | Merrill Lynch |
| 2026-06-17 | Karydas DaphneOfficer | 3K | $75K | 0.004% | 2026-06-17 | Merrill Lynch |
| 2026-06-15 | Rodman David MalcomOfficer | 10K | $235K | 0.012% | 2026-06-15 | Merrill Lynch |
| 2026-06-12 | Rodman David MalcomOfficer | 6K | $152K | 0.008% | 2026-06-12 | Merrill Lynch |
| 2026-06-10 | Rodman David MalcomOfficer | 2K | $54K | 0.003% | 2026-06-10 | Merrill Lynch |
| 2026-05-18 | Rodman David MalcomOfficer | 417 | $11K | 0.001% | 2026-05-18 | Merrill Lynch |
| 2026-05-13 | Rodman David MalcomOfficer | 14K | $402K | 0.017% | 2026-05-13 | Merrill Lynch |
| 2026-05-12 | Rodman David MalcomOfficer | 6K | $186K | 0.008% | 2026-05-12 | Merrill Lynch |
| 2026-05-11 | Rodman David MalcomOfficer | 2K | $65K | 0.003% | 2026-05-11 | Merrill Lynch |
| 2026-04-17 | Rodman David MalcomOfficer | 416 | $13K | 0.001% | 2026-04-17 | Merrill Lynch |
| 2026-04-15 | Rodman David MalcomOfficer | 6K | $176K | 0.008% | 2026-04-15 | Merrill Lynch |
| 2026-04-13 | Rodman David MalcomOfficer | 14K | $373K | 0.017% | 2026-04-13 | Merrill Lynch |
| 2026-04-13 | Congleton JonOfficer | 16K | $422K | 0.019% | 2026-04-13 | Merrill Lynch |
| 2026-04-09 | Rodman David MalcomOfficer | 2K | $59K | 0.003% | 2026-04-09 | Merrill Lynch |
| 2026-03-31 | Karydas DaphneOfficer | 3K | $75K | 0.004% | 2026-03-31 | Merrill Lynch |
| 2026-03-31 | Congleton JonOfficer | 75K | $2.0M | 0.091% | 2026-03-31 | Merrill Lynch |
| 2026-03-17 | Rodman David MalcomOfficer | 417 | $11K | 0.001% | 2026-03-17 | Merrill Lynch |
| 2026-03-13 | Rodman David MalcomOfficer | 14K | $369K | 0.018% | 2026-03-13 | Merrill Lynch |
| 2026-03-12 | Rodman David MalcomOfficer | 6K | $174K | 0.008% | 2026-03-12 | Merrill Lynch |
| 2026-03-09 | Rodman David MalcomOfficer | 2K | $58K | 0.003% | 2026-03-09 | Merrill Lynch |
| 2026-02-17 | Rodman David MalcomOfficer | 417 | $12K | 0.001% | 2026-02-17 | Merrill Lynch |
| 2026-02-13 | Rodman David MalcomOfficer | 14K | $386K | 0.018% | 2026-02-13 | Merrill Lynch |
| 2026-02-12 | Rodman David MalcomOfficer | 6K | $184K | 0.008% | 2026-02-12 | Merrill Lynch |
| 2026-02-09 | Rodman David MalcomOfficer | 2K | $66K | 0.003% | 2026-02-09 | Merrill Lynch |
| 2026-01-20 | Rodman David MalcomOfficer | 416 | $13K | 0.001% | 2026-01-20 | Merrill Lynch |
| 2026-01-14 | Rodman David MalcomOfficer | 11K | $371K | 0.014% | 2026-01-14 | Merrill Lynch |
| 2026-01-13 | Rodman David MalcomOfficer | 8K | $252K | 0.010% | 2026-01-13 | Merrill Lynch |
| 2026-01-12 | Rodman David MalcomOfficer | 6K | $205K | 0.008% | 2026-01-12 | Merrill Lynch |
| 2026-01-12 | Levy Adam ScottOfficer | 11K | $346K | 0.014% | 2026-01-12 | Merrill Lynch |
Large holders (13D and 13G)
One row per reporting person with its latest filing, newest first. JSON7 holders report 5% or more of MLYS in their latest filing, all on Schedule 13G (passive). The largest reported stake is Catalys Pacific Fund, LP at 10.1% of the class (8,002,738 shares), filed 2026-02-13 for an event on 2025-12-31.
| Filed | Form | Holder | Shares | Of class | Event |
|---|---|---|---|---|---|
| 2026-08-06 | 13G/Ano. 1 | FMR LLCparent holding company | 4.5M | 5.1% | 2026-06-30 |
| 2026-08-06 | 13G/Ano. 1 | Abigail P. Johnsonindividual | 4.5M | 5.1% | 2026-06-30 |
| 2026-02-13 | 13G/Ano. 3 | Catalys Pacific Fund, LPpartnership | 8.0M | 10.1% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 3 | Catalys Pacific Fund GP, LPpartnership | 8.0M | 10.1% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 3 | Catalys Pacific, LLCother entity | 8.0M | 10.1% | 2025-12-31 |
| 2026-02-13 | 13G/Ano. 3 | Brian Taylor Slingsbyindividual | 8.0M | 10.1% | 2025-12-31 |
| 2026-01-21 | 13G | BlackRock, Inc.parent holding company | 4.1M | 5.2% | 2025-12-31 |
13F holders
Tracked managers holding MLYS at their latest 13F. JSON6 of the 30 tracked managers held MLYS at their latest 13F, $73.8M in total at quarter-end prices. Millennium Management is the largest at $33.0M (0.0% of its portfolio) as of 2026-06-30. Over the prior quarter 2 added shares and 4 cut.
| Fund | Quarter | Shares | Value | Of portfolio | Change in shares |
|---|---|---|---|---|---|
| Millennium Management | 2026-06-30 | 1.2M | $33.0M | 0.01% | +696K |
| Citadel Advisors | 2026-06-30 | 468K | $12.6M | 0.00% | -132K |
| Renaissance Technologies | 2026-06-30 | 378K | $10.2M | 0.01% | -5K |
| D. E. Shaw & Co. | 2026-06-30 | 353K | $9.5M | 0.00% | -534K |
| Two Sigma Investments | 2026-06-30 | 162K | $4.4M | 0.00% | -149K |
| AQR Capital Management | 2026-06-30 | 153K | $4.1M | 0.00% | +3K |
Only the 30 tracked managers on the funds hub; a 13F reports long positions in US listed stock at quarter end, 45 days late, and says nothing about shorts or positions sold since.
What this page is
Mineralys Therapeutics in the regulatory record
Regulators publish company data in separate files that never sit next to each other: FINRA's twice-monthly short interest, its daily short sale volume, the SEC's fails-to-deliver counts, and each insider's Form 4. A company page puts those series for one ticker on one URL, with planned sales, large holders, 13F holders and financials beside them, so the short position, the daily flow, the settlement fails and what insiders are doing can be read together.
Each section has its own history table, a one-line summary of the latest figures and its own JSON and CSV links, and says when its source last updated.
This page follows Mineralys Therapeutics (MLYS), SEC CIK 1933414, listed on Nasdaq, classified by the SEC as pharmaceutical preparations. The cross-market tables live on the short interest and insider transactions hubs.
Source and updates
- Short interest
- FINRA consolidated short interestSource: FINRA.Twice a month, about eight business days after settlement. Latest 2026-10-15.JSON and CSV
- Daily short volume
- FINRA Reg SHO daily filesSource: FINRA.Every trading day, the morning after FINRA posts it. Latest 2026-11-02.JSON and CSV
- Fails to deliver
- SEC fails-to-deliver dataSource: SEC.Twice a month, a few weeks after the half month ends. Latest 2026-10-02.JSON and CSV
- Planned sales
- SEC EDGAR Form 144Source: SEC.New notices appear shortly after the SEC posts them; a notice is filed on or before the sale. Latest 2026-10-13.JSON and CSV
- Large holders
- SEC EDGAR Schedule 13D and 13GSource: SEC.New filings appear shortly after the SEC posts them. A 13D is due within five business days of crossing 5%; a 13G follows the passive schedule. Latest 2026-08-06.JSON and CSV
- 13F holders
- SEC EDGAR Form 13F-HRSource: SEC.Quarterly, filed within 45 days of quarter end; 30 tracked managers. Latest 2026-06-30.JSON and CSV
- Earnings dates
- SEC EDGAR 8-K filings (Item 2.02)Source: SEC.Twice a day. Reported dates come from the company's 8-K filings; the next date is marked as an estimate until the 8-K arrives. Latest 2026-08-11.JSON and CSV
- Insider trades
- SEC EDGAR Form 4Source: SEC.New filings appear shortly after the SEC posts them; they're due two business days after the trade. Latest 2026-10-19.JSON and CSV
- Company record
- EDGAR filing index for CIK 1933414Ticker, name and exchange from the SEC's company list, refreshed weekly.
- Rate limits
- 10 requests a minute without a key, 30 with a free key from a free account.
How to read it
- Read the position against the flow: rising short interest with a high daily short share is new shorting; rising short interest with a normal short share is old shorts holding on.
- Insider buys next to a large short position are rare and stand out; insider sells next to one are common and mean little.
- Fails to deliver matter relative to the float, not in absolute shares; a million failed shares in a mega cap is noise.
Analysis of what the data shows, not advice. XOOMAR does not recommend buying, selling or holding anything.
Other companies the SEC classifies as pharmaceutical preparations
Other company pages
- STESTERIS
- STLDSteel Dynamics
- STRCStrategy
- STRLSterling Infrastructure
- STTState Street
- STXSeagate Technology Holdings
- STZConstellation Brands
- SUISun Communities
- SUNBSunbelt Rentals Holdings
- SWSmurfit Westrock
- SWKStanley Black & Decker
- SWKSSkyworks Solutions
- SXTCChina SXT Pharmaceuticals
- SYFSynchrony Financial
- SYKStryker
- SYNASynaptics
Datasets
Frequently Asked Questions
How much of MLYS is sold short?
7,438,452 shares were held short at the 2026-10-15 settlement, 5.3 days of average volume. FINRA publishes the next count about eight business days after the 15th and the last business day of the month.
What is MLYS's daily short volume?
On 2026-11-02, 329,646 of the 1,654,948 MLYS shares reported to FINRA were sold short, 19.9% of the day's reported volume. Short volume is a flow for one day, not a position.
Does MLYS have fails to deliver?
The SEC's latest file shows 1,330 MLYS shares failed to deliver at settlement 2026-10-02. Fails are reported per settlement date and published twice a month with a lag.
Are MLYS insiders buying or selling?
Insiders at MLYS reported 6 open-market sells worth $5.5M in the last 90 days and no open-market buys. Latest filing: COATS LONNEL (Director) on 2026-10-19.
Have MLYS insiders filed to sell?
50 Form 144 notices on file for MLYS worth $19.2M at the prices reported; 12 in the last 90 days worth $6.2M. Latest: Rodman David Malcom filed on 2026-10-13 to sell 3,542 shares ($78K) from 2026-10-13.
Who owns 5% or more of MLYS?
7 holders report 5% or more of MLYS in their latest filing, all on Schedule 13G (passive). The largest reported stake is Catalys Pacific Fund, LP at 10.1% of the class (8,002,738 shares), filed 2026-02-13 for an event on 2025-12-31.
Which tracked 13F managers own MLYS?
6 of the 30 tracked 13F managers held MLYS shares at their latest filing, $73.8M in all. The largest: Izzy Englander's Millennium Management (1.2M shares, $33.0M), Ken Griffin's Citadel Advisors (468K shares, $12.6M), Renaissance Technologies (378K shares, $10.2M), D. E. Shaw & Co. (353K shares, $9.5M), Two Sigma Investments (162K shares, $4.4M), Cliff Asness's AQR Capital Management (153K shares, $4.1M).
Data on this page is provided for informational purposes only and is not financial advice. See our editorial policy.